67 related articles for article (PubMed ID: 20656222)
1. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
[TBL] [Abstract][Full Text] [Related]
2. Bridging locoregional treatment prior to liver transplantation for cirrhotic patients with hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.
Kostakis ID; Dimitrokallis N; Iype S
Ann Gastroenterol; 2023; 36(4):449-458. PubMed ID: 37396004
[TBL] [Abstract][Full Text] [Related]
3. Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: A systematic review and meta-analysis.
Arvind A; Seif El Dahan K; Malhotra R; Daher D; Rich NE; Patel MS; VanWagner LB; Lieber SR; Cotter TG; Louissaint J; Mufti AR; Kulik L; Pillai A; Parikh ND; Singal AG
Liver Transpl; 2024 Jun; 30(6):595-606. PubMed ID: 38466889
[TBL] [Abstract][Full Text] [Related]
4. Improving prognostication in patients with hepatocellular carcinoma undergoing loco-regional therapy using pre- and post-locoregional therapy scores.
Thandassery RB; Lavender CA; Perisetti A; Beheshti M
Abdom Radiol (NY); 2024 Feb; 49(2):631-641. PubMed ID: 38071274
[TBL] [Abstract][Full Text] [Related]
5. Effect of Locoregional Treatments in Hepatocellular Carcinoma: What Are the Pathologic/Radiologic Milan Criteria?
Aksoy F; Dundar HZ; Celik F; Ongen G; Nas OF; Saglam K; Gurluer E; Kıyıcı M; Kaya E
Exp Clin Transplant; 2023 Oct; 21(10):820-825. PubMed ID: 37965957
[TBL] [Abstract][Full Text] [Related]
6. Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant.
Liu MC; Lizaola-Mayo B; Jayasekera CR; Mathur AK; Katariya N; Aqel B; Byrne TJ; Chascsa DMH
J Gastrointest Cancer; 2024 Jun; 55(2):969-974. PubMed ID: 38483692
[TBL] [Abstract][Full Text] [Related]
7. A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma.
Chaib E; Amaku M; Coutinho FA; Lopez LF; Burattini MN; D'Albuquerque LA; Massad E
Theor Biol Med Model; 2013 Oct; 10():60. PubMed ID: 24139285
[TBL] [Abstract][Full Text] [Related]
8. Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.
Thornton LM; Abi-Jaoudeh N; Lim HJ; Malagari K; Spieler BO; Kudo M; Finn RS; Lencioni R; White SB; Kokabi N; Jeyarajah DR; Chaudhury P; Liu D
J Vasc Interv Radiol; 2024 Jun; 35(6):818-824. PubMed ID: 38789204
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Access to Liver Transplant Referral and Evaluation among Patients with Hepatocellular Carcinoma in Georgia.
Ross-Driscoll K; Ayuk-Arrey AT; Lynch R; McCullough LE; Roccaro G; Nephew L; Hundley J; Rubin RA; Patzer R
Cancer Res Commun; 2024 Apr; 4(4):1111-1119. PubMed ID: 38517133
[TBL] [Abstract][Full Text] [Related]
10. A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit.
Su CW; Teng W; Lin PT; Wu TH; Hsu YC; Hsieh YC; Huang CH; Chen WT; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2023; 13(11):5482-5492. PubMed ID: 38058809
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma: tumor heterogeneity and recurrence after preoperative locoregional therapy.
Espírito Santo J; Ladeirinha A; Alarcão A; Strelet E; Reis M; Santos R; Carvalho L
Med Oncol; 2023 Oct; 40(12):340. PubMed ID: 37882867
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of jaundice in advanced hepatocellular carcinoma - a sub-Saharan perspective.
Keshaw PB; Bernon M; Emmamally M; Khan R; Segobin R; Creamer D; Krige JEJ; Jonas E; Sobnach S
S Afr J Surg; 2024 May; 62(2):18-22. PubMed ID: 38838114
[TBL] [Abstract][Full Text] [Related]
13. Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission.
Woodrell CD; Goldstein NE; Moreno JR; Schiano TD; Schwartz ME; Garrido MM
J Pain Symptom Manage; 2021 May; 61(5):940-947.e3. PubMed ID: 33035651
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Locoregional Therapy May Relate with Stemness and Distinct Transitions Between Epithelial and Mesenchymal States in Hepatocellular Carcinoma.
Espírito Santo J; Ladeirinha A; Alarcão A; Strelet E; Reis M; Santos R; Carvalho L
J Clin Exp Hepatol; 2024; 14(1):101268. PubMed ID: 38076372
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.
Moon AM; Cook S; Swier RM; Sanoff HK; Kappelman MD; Wagner LI; Barritt AS; Singal AG; Shah ND; Mauro DM; Yanagihara TK; Gerber DA; Fried MW; Brown C; Waheed M; Teal R; Evon DM
Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37930127
[TBL] [Abstract][Full Text] [Related]
16. Biomarker predictors and LRT strategies for HCC recurrence post-liver transplantation: A comment.
He T; Sun K; Zou J
J Hepatol; 2024 Jun; ():. PubMed ID: 38851452
[No Abstract] [Full Text] [Related]
17. Enhancing childhood obesity prevention through Milan systemic family therapy.
Pohan RA; Hidayah N; Ramli M; Atmoko A; Akbar S
J Public Health (Oxf); 2024 Jun; ():. PubMed ID: 38909169
[No Abstract] [Full Text] [Related]
18. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.
Mendiratta-Lala M; Aslam A; Maturen KE; Westerhoff M; Maurino C; Parikh ND; Sun Y; Sonnenday CJ; Stein EB; Shampain KL; Kaza RK; Cuneo K; Masch W; Do RKG; Lawrence TS; Owen D
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):704-714. PubMed ID: 34644607
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.
Rogatko CP; Weisse C; Schwarz T; Berent AC; Diniz MA
J Vet Intern Med; 2021 May; 35(3):1487-1495. PubMed ID: 33955600
[TBL] [Abstract][Full Text] [Related]
20. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
